CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 65 enrolled
Drug / intervention
Vilazodone; Viibryd +1 moredrug
Likely dose
Vilazodone; Viibryd 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01608295
NCT01608295Phase 4Completed
CompareCT.gov

A Pilot Study of Double-blind Comparison of Vilazodone to Paroxetine in Geriatric Depression

University of California, Los Angeles·interventional·Posted May 31, 2012·Updated May 11, 2018

In Brief

A Phase 4 clinical trial evaluating Vilazodone; Viibryd and Paroxetine; Paxil for Major Depressive Disorder. Completed, enrolled 65 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the effects of vilazodone for the treatment of depression in older adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
CollaboratorsForest Laboratories

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 31, 2012
Enrollment StartJul 1, 2012
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 14.1 years ago

Interventions

Vilazodone; Viibryddrug

Subjects randomized to receive vilazodone blindly will have incremental dose titration of 10mg per day for the 1st week; 20mg per day the 2nd week; 40mg per day for the 3rd-12th week. Doses of the drugs will be adjusted according to individual tolerability and safety.

Paroxetine; Paxildrug

Subjects randomized to receive paroxetine blindly will have incremental dose titration of paroxetine 10mg per day for the 1st week; 20mg per day for the 2nd week; and 30mg per day for the 3rd-12 week. Doses of the drugs will be adjusted according to individual tolerability and safety.